Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.05, read 2026-11-03
Ethical does not pass the values gate
Price17.03 USD
Fair value11.64
Ethical score30.0/100
Value readOvervaluedas of 3 Nov 2026
Our investment reviews on this name
2026-10-02Read Accumulation13.70+24.3% to today ✓Markup gives way to Accumulation after a 14% rise in 9 weeks
2026-08-01Read Markup12.02+41.7% to today ✓Distribution gives way to Markup after an 11% rise in 4 weeks
2026-07-02Read Distribution10.84+57.1% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Hagerty, Inc. holds its Accumulation at $17.03. The statistical read favours the sellers, held for 40 days.
As held on the ledger · 2026-11-03
Phase
Accumulation
Quantitative state
The statistical read favours the sellers, held for 40 days
Price at the screen
$17.03
Valuation
141.55 trailing · 26.60 forward price to earnings
Values screen
FAIL· score 30.0
Beta
0.83
The Workings
Five Screens, Shown in Full
Does not pass. Prohibited keyword in sector/industry: insurance
Test
Figure
Limit
What it means
Status
Business activity
Excluded
Core business clean
Prohibited keyword in sector/industry: insurance
Fail
Debt load
Excluded
Below 33%
Interest-bearing debt is of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
Excluded
Below 33%
Interest-bearing cash and securities are of assets, above the one-third limit.
Fail
Receivables
Excluded
Below 49%
Money owed to the company is of assets, above the 49% limit.
Fail
Revenue purity
Excluded
Below 5%
of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Hagerty, does not clear the screen at the business-activity stage. It operates in conventional financial services, which the screen treats as interest-based, so the financial ratios are not the deciding factor here.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when HGTY's ethical verdict changes
Today HGTY does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 3 Nov 2026: it trades above our $11.64 fair value estimate.
Fair value range in USD, drawn from the 2026-11-03 screen. The gold marker is the market price at the same screen. The price runs 46.3% above the base estimate.
Where our models see it going: fair-value estimate $11.64, with a range of $11.64 to $13.39, dated to the 2026-11-03 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Collector Car Cover Hits an Ethical Wall
Every time an owner polishes a classic car and hunts for specialist cover, the premiums pass through a niche player like Hagerty that targets enthusiast vehicles across three countries. Revenue is already shrinking 5 percent, margins sit at just 2 percent, and the shares trade above our fair value with a negative margin of safety.
We pass outright. The business fails our ethical screen on insurance, and a 21 times forward multiple on declining top-line numbers offers no attraction even before the screen is applied. Analyst targets around 13 dollars change nothing here.
This is exactly what the screen is for. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
HGTY trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-03Accumulation$15.58+0.0%Entry 16
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (7 analysts) rates it hold, with a mean price target of $13. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Accumulation$15.58+0.0%Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (7 analysts) rates it hold, with a mean price target of $13. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Accumulation$15.58+0.1%Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (7 analysts) rates it hold, with a mean price target of $13. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Accumulation$15.57+0.0%Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (7 analysts) rates it hold, with a mean price target of $13. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Accumulation$15.57+0.0%Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (7 analysts) rates it hold, with a mean price target of $13. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Accumulation$15.57+0.0%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (7 analysts) rates it hold, with a mean price target of $13. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Accumulation$15.57+3.9%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 3.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (7 analysts) rates it hold, with a mean price target of $13. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Accumulation$14.99+0.0%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (7 analysts) rates it hold, with a mean price target of $13. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Accumulation$14.99+0.0%Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (7 analysts) rates it hold, with a mean price target of $13.
2026-10-18Accumulation$14.99+9.4%Entry 7
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 9.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (7 analysts) rates it hold, with a mean price target of $13.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
